Takeda's future under review

Published: 8-Dec-2006
Media

Despite an expected 11% rise in pretax profits for the fiscal year ending 31 March, Japanese company Takeda Pharmaceutical\'s future is said to be under review.


Despite an expected 11% rise in pretax profits for the fiscal year ending 31 March, Japanese company Takeda Pharmaceutical's future is said to be under review.

Industry analysts consider one cause for uncertainty is the company's diabetic agent Actos, marketed in the US; although sales are increasing, global leader US-based Merck & Co and Swiss company Novartis are preparing to launch their own diabetic drugs next fiscal year.

The viability of new drug candidates is also contributing to market wariness, as Takeda has yet to disclose the clinical test results for hypertension and diabetes drugs.

The firm plans to boost its lineup of antibody drugs and fortify sales channels in Europe via acquisitions. With cash reserves of ¥1.7 trillion, the key for Take da will be how quickly it can spend the ¥1 trillion earmarked for acquisitions.

See more

You may also like

Media

Only a handful of pharma companies are developing the urgently needed new medicines for the poor

Read more
The development of new medical products that are considered the highest priority for people in developing countries is highly concentrated – among five pharmaceutical companies and on five diseases

Trending Articles

  1. Can Aztekin receives Rising Star Award 2025 from the International Society of Regenerative Biology
  2. Royal Society of Chemistry and TIB co-create next generation Open Access consortium model The agreement delivers shared goals of equity for institutions, a community approach and universal open access for authors
  3. BioIVT acquires Optivia Biotechnology The acquisition strengthens BioIVT’s transporter sciences capabilities and will enable it to partner with customers on new drug applications and mechanistic studies related to transporters
  4. The Lab Awards: from balances to the ball The Lab Awards, the leading awards ceremony for the UK’s laboratory industry, was held at The Vox, Birmingham, on 1 November and celebrated the lab industry’s key achievements from the past year
  5. Reaping the benefits of a continuous process Growing interest in continuous processing reflects expectations that technological innovation can benefit operations across the board, says Guy Tiene, That’s Nice Director of Strategic Content

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Media

Only a handful of pharma companies are developing the urgently needed new medicines for the poor

The development of new medical products that are considered the highest priority for people in developing countries is highly concentrated – among five pharmaceutical companies and on five diseases
Media

Takeda shows significant profit dip in Q1

Takeda will be looking to Shire’s drug pipeline to bolster future sales after disappointing Q1 results, says GlobalData
Media

GlobalData publishes analysis of top 25 global pharma companies

The data and analytics company has tracked the market cap performance of the top 25 pharma companies for the quarter ending 31 March, 2018 compared to 2017 revealing a number of interesting insights
Media

GlobalData names top 25 global pharma companies by market cap

The performance highlights of the top 25 publicly traded global pharma companies for the year 2017 have been confirmed in the latest research from GlobalData
Media

Takeda expands into Brazil

<p>Japan\'s largest drugmaker, Takeda Pharmaceutical Company, is to set up a subsidiary in Brazil. </p>
Media

Takeda to integrate Irish manufacturing operations

<p>Japanese pharmaceutical company Takeda Pharmaceutical is to integrate its subsidiaries Takeda Ireland (TIL) in Kilruddery and Takeda Pharma Ireland (TPI) in Dublin into a single operation on 1 July. All TPI assets will be transferred to TIL and TPI will be liquidated.</p>
Media

Takeda to acquire Millennium for US$8.8bn

<p>Takeda Pharmaceutical Company, of Japan, has signed a definitive agreement to purchase US biopharmaceutical company Millennium Pharmaceuticals for approximately US$8.8bn (Euro 5.53bn).</p>
Subscribe now